Treatment regimens for multiple myeloma have expanded significantly over the last decade and have improved outcomes in patients. This expansion has created knowledge and practice gaps among community oncology providers in administration protocol and adverse event (AE) management.
The goal of this project was to assess practice patterns, monitoring and management of treatment-related AEs, supportive care services, and barriers to treatment for patients with multiple myeloma.
For more information on this study contact Mary Stanley, LMSW, PMP at mstanley@accc-cancer.org.
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.

A recent discussion between ACCC and Highlands Oncology centered on how artificial intelligence can be implemented thoughtfully in cancer care to support clinicians and operations without compromising clinical judgement or patient care.

Small Cell SMASHERS was founded in 2023 as a patient-centered advocacy and education community designed to challenge long-standing narratives about small cell lung cancer and restore a sense of voice, connection, and hope for patients and their loved ones.

ACCCBuzz spoke with Fox Chase Cancer Center to learn more about its partnership with Omniscope, a leader in advanced molecular profiling technology, in hopes of developing an assay that accurately predicts which patients will respond well to immunotherapy based on the presence of certain T-cell clones.

On Friday, April 17, ACCC welcomed oncology leaders from around the country to Washington, DC for the inaugural ACCC Leadership Summit, a forum designed for executive-level decision-makers to engage in strategic dialogue, peer-to-peer exchange, and actionable insights at the highest level of oncology leadership.
